|
Recovery% ± SD |
Sample |
Reported methodsc |
Proposed methods |
|
Method A |
Method B |
Method C |
Factive Tablets |
|
|
|
|
X ± SDa |
100.08 ± 0.56 |
99.84 ± 0.69 |
100.20 ± 0.72 |
99.65 ± 0.48 |
t-Valueb |
|
0.60 |
0.29 |
1.30 |
F-Valueb |
|
1.52 |
1.65 |
1.36 |
Flobiotic tablets |
|
|
|
|
X ± SDa |
99.94 ± 0.68 |
100.15 ± 0.82 |
99.70 ± 0.47 |
99.80 ± 0.60 |
t-Valueb |
|
0.44 |
0.65 |
0.35 |
F-Valueb |
|
1.45 |
2.09 |
0.77 |
GemiQue tablets |
|
|
|
|
X ± SDa |
99.85 ± 0.49 |
99.45 ± 0.65 |
100.10 ± 0.53 |
99.50 ± 0.37 |
t-Valueb |
|
1.10 |
0.77 |
1.27 |
F-Valueb |
|
1.76 |
1.17 |
1.75 |
Avelox® tablets |
|
|
|
|
X ± SDa |
99.03 ± 0.97 |
99.60 ± 1.16 |
99.70 ± 0.84 |
99.40 ± 0.76 |
t-Valueb |
|
0.84 |
1.17 |
0.67 |
F-Valueb |
|
1.43 |
1.33 |
1.63 |
Moxiflox tablets |
|
|
|
|
X ± SDa |
99.34 ± 0.34 |
99.54 ± 0.42 |
99.58 ± 0.50 |
99.70 ± 0.48 |
t-Valueb |
|
0.83 |
0.89 |
1.37 |
F-Valueb |
|
1.53 |
2.16 |
1.99 |
Moxifloxacin tablets |
|
|
|
|
X ± SDa |
99.94 ± 0.92 |
99.90 ± 0.88 |
100.20 ± 1.15 |
100.05 ± 1.20 |
t-Valueb |
|
0.07 |
0.39 |
0.16 |
F-Valueb |
|
1.09 |
1.56 |
1.70 |
aMean for six independent analyses.
bTheoretical values for t and F-values at five degree of freedom and 95% confidence limit are (t=2.57) and (F=5.05).
cReference spectrophotometric methods for GMF [39] and MXF [50]. |